Advertisement

Journal of Molecular Medicine

, Volume 92, Issue 1, pp 53–64 | Cite as

Gemifloxacin inhibits migration and invasion and induces mesenchymal–epithelial transition in human breast adenocarcinoma cells

  • Tun-Chieh Chen
  • Ya-Ling Hsu
  • Yu-Chieh Tsai
  • Yu-Wei Chang
  • Po-Lin Kuo
  • Yen-Hsu Chen
Original Article

Abstract

Gemifloxacin (GMF) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. The aim of this study was to investigate the anti-metastatic activities of GMF and its possible mechanisms of action, with a special focus on the induction of mesenchymal–epithelial transition (MET). The human breast adenocarcinoma cell lines MDA-MB-231 and MDA-MB-453 were used to assess the anti-metastatic activity of GMF on cell migration and invasion and in scratch wound-healing assays. The effects of GMF on the MET and its regulatory nuclear factor κB (NF-κB)/Snail pathway were assessed. The in vivo anti-metastatic effect of GMF was also evaluated in an animal model. This study demonstrated that GMF inhibited the migration and invasion of MDA-MB-231 and MDA-MB-453 cells and induced the MET. GMF suppressed the activation of NF-κB, as well as the cell migration and invasion induced by tumor necrosis factor α (TNF-α). GMF was shown to inhibit the phosphorylation of the inhibitor of κB (IκB) and the translocation of NF-κB/Snail in both cancer cell lines. This study showed that the Raf kinase inhibitor protein (RKIP), an inhibitor of IκB kinase, is upregulated after GMF treatment. Inhibition of RKIP by small hairpin RNA transfection significantly decreased the inhibitory effect of GMF on the NF-κB/Snail pathway and also inhibited cell migration and invasion. Overexpression of Snail suppressed GMF-mediated metastasis inhibition and E-cadherin upregulation. An animal model revealed that GMF effectively inhibits lipopolysaccharide-mediated metastasis in mice. This study has demonstrated that GMF might be a novel anticancer agent for the prevention and treatment of metastasis in breast cancer.

Key messages

  • GMF inhibits the migration and invasion of human breast adenocarcinoma cells.

  • GMF induces MET by reducing NF-κB and Snail activation and by increasing RKIP levels.

  • GMF has potential clinical implication as an anti-metastatic agent for breast cancer.

Keywords

Gemifloxacin Breast cancer Metastasis NF-κB RKIP 

Abbreviations

GMF

Gemifloxacin

MET

Mesenchymal–epithelial transition

NF-κB

Nuclear factor κB

RKIP

Raf kinase inhibitor protein

IKK

IκB kinase

LPS

Lipopolysaccharide

FBS

Fetal bovine serum

TNF-α

Tumor necrosis factor α

PCR

Polymerase chain reaction

shRNA

Small hairpin RNA

H&E

Hematoxylin and eosin

Notes

Acknowledgments

This study is supported by grants from the National Science Council of Taiwan (NSC 102-2628-B-037-002-MY3) and Excellence for Cancer Research Center Grant, the Department of Health, Executive Yuan, Taipei, Taiwan (DOH102-TD-C-111-002) and Kaohsiung Medical University Research Foundation (KMUER008 and KMU-Q102017) and Kaohsiung Municipal Ta-Tung Hospital (KMTTH-1-99-028). The authors thank the Center for Resources, Research, and Development of Kaohsiung Medical University for their support.

Conflict of interest

There are no potential conflicts of interest.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. Cancer J Clin 59:225–249CrossRefGoogle Scholar
  2. 2.
    Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T (1993) The lifetime risk of developing breast cancer. J Natl Cancer Inst 85:892–897PubMedCrossRefGoogle Scholar
  3. 3.
    Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial–mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68:989–997PubMedCrossRefGoogle Scholar
  4. 4.
    Micalizzi DS, Farabaugh SM, Ford HL (2010) Epithelial–mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15:117–134PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP (2009) Stabilization of Snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15:416–428PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8:197–209PubMedCrossRefGoogle Scholar
  7. 7.
    Prasad S, Ravindran J, Aggarwal BB (2010) NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336:25–37PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Watanabe S et al (2009) Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 100:1668–1674PubMedCrossRefGoogle Scholar
  9. 9.
    Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC (2005) The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12(Suppl 1):S37–S46PubMedCrossRefGoogle Scholar
  10. 10.
    Fritz RD, Radziwill G (2010) CNK1 promotes invasion of cancer cells through NF-kappaB-dependent signaling. Mol Cancer Res 8:395–406PubMedCrossRefGoogle Scholar
  11. 11.
    Bonavida B, Baritaki S (2011) Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kappaB/Snail/YY1/RKIP circuitry. Nitric Oxide 24:1–7PubMedCrossRefGoogle Scholar
  12. 12.
    Zeng L, Imamoto A, Rosner MR (2008) Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets 12:1275–1287PubMedCrossRefGoogle Scholar
  13. 13.
    Baritaki S, Bonavida B (2010) Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes. Crit Rev Immunol 30:31–46PubMedCrossRefGoogle Scholar
  14. 14.
    Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B (2004) Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91:169–200PubMedGoogle Scholar
  15. 15.
    Lowe MN, Lamb HM (2000) Gemifloxacin. Drugs 59:1137–1147PubMedCrossRefGoogle Scholar
  16. 16.
    Paul M, Gafter-Gvili A, Fraser A, Leibovici L (2007) The anti-cancer effects of quinolone antibiotics? Eur J Clin Microbiol Infect Dis 26:825–831PubMedCrossRefGoogle Scholar
  17. 17.
    Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG (2006) Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690–695PubMedCrossRefGoogle Scholar
  18. 18.
    Hara S, Ishimatsu Y, Mukae H, Sakamoto N, Kakugawa T, Fujita H, Hara A, Kohno S (2011) Anti-inflammatory effects of garenoxacin on IL-8 production and ERK1/2 activation induced by lipopolysaccharides in A549 and THP-1 cells. Eur J Pharmacol 668:264–270PubMedCrossRefGoogle Scholar
  19. 19.
    Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, Supino R, Zunino F (1997) New developments in antitumor anthracyclines. Pharmacol Ther 76:117–124PubMedCrossRefGoogle Scholar
  20. 20.
    Cho SY, Choi HY (1980) Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study. Am J Clin Pathol 73:232–234PubMedGoogle Scholar
  21. 21.
    Wu Y, Zhou BP (2010) TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 102:639–644PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431PubMedCrossRefGoogle Scholar
  23. 23.
    Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, Ju X, Ojeifo J, Jiao X, Yeow WS, Katiyar S et al (2010) The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 70:10464–10473PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, Sarkar FH (2011) Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat 126:15–25PubMedCrossRefGoogle Scholar
  25. 25.
    Paul S, DeCastro AJ, Lee HJ, Smolarek AK, So JY, Simi B, Wang CX, Zhou R, Rimando AM, Suh N (2010) Dietary intake of pterostilbene, a constituent of blueberries, inhibits the beta-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis 31:1272–1278PubMedCrossRefGoogle Scholar
  26. 26.
    Van Waes C (2007) Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13:1076–1082PubMedCrossRefGoogle Scholar
  27. 27.
    Sinclair S, Swain SM (2010) Primary systemic chemotherapy for inflammatory breast cancer. Cancer 116:2821–2828PubMedCrossRefGoogle Scholar
  28. 28.
    Hou Z, Peng H, White DE, Wang P, Lieberman PM, Halazonetis T, Rauscher FJ 3rd (2010) 14-3-3 binding sites in the Snail protein are essential for Snail-mediated transcriptional repression and epithelial–mesenchymal differentiation. Cancer Res 70:4385–4393PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Szasz AM, Nemeth Z, Gyorffy B, Micsinai M, Krenacs T, Baranyai Z, Harsanyi L, Kiss A, Schaff Z, Tokes AM et al (2011) Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Cancer Sci 102:2248–2254PubMedCrossRefGoogle Scholar
  30. 30.
    Tang H, Park S, Sun SC, Trumbly R, Ren G, Tsung E, Yeung KC (2010) RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex. FEBS Lett 584:662–668PubMedCrossRefGoogle Scholar
  31. 31.
    Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, Liang H, Li WH, Ishwaran H, Minn AJ et al (2011) Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J 30:4500–4514PubMedCrossRefGoogle Scholar
  32. 32.
    Hao C, Wei S, Tong Z, Li S, Shi Y, Wang X, Zhu ZH (2012) The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro. Tumour Biol 33:1159–1167PubMedCrossRefGoogle Scholar
  33. 33.
    Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC (2008) Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27:2243–2248PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B (2009) Pivotal roles of Snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res 69:8376–8385PubMedCrossRefGoogle Scholar
  35. 35.
    Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R et al (2012) Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 72:3091–3104PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Internal MedicineKaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan
  2. 2.Division of Infectious Diseases, Department of Internal MedicineKaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan
  3. 3.Graduate Institute of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  4. 4.Faculty of Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  5. 5.Department of Pathology and LaboratoryKaohsiung Veterans General HospitalKaohsiungTaiwan
  6. 6.Institute of Clinical Medicine, College of MedicineKaohsiung Medical UniversityKaohsiungTaiwan
  7. 7.Cancer CenterKaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan
  8. 8.Department of Medical ResearchKaohsiung Medical University Hospital, Kaohsiung Medical UniversityKaohsiungTaiwan

Personalised recommendations